BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag
Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.
Victoria Advocate7d
Novo Nordisk To Pay $2 Billion for New Weight Loss Drug
Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...
The Australian Financial Review23d
Ozempic maker says its Australian market could be half the population
Novo Nordisk executive Camilla Sylvest says Australia generally has a relatively high prevalence of obesity compared with many other countries. Asked about the potential size of the Australian ...
Novo Nordisk membership in UK pharma body restored after suspension
Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension ...
Devdiscourse4d
Health Headlines: Delayed Laws, Market Woes, and Emerging Treatments
The proposed UK assisted dying law may be delayed until 2029, raising doubts about its future. Novo Nordisk's shares tumble ...
Ozempic ingredient linked to dangerous eye condition that could threaten sight
A new study adds to evidence to suggest the main ingredient in Novo Nordisk’s injectable drug for type 2 diabetes may ...
The Motley Fool6d
Is Novo Nordisk Stock a Buy?
The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...